Search Results 881-890 of 17090 for monoclonal antibody

  1. Publications - Paschalis Vergidis, M.D., M.S. - Mayo Clinic

    Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients ... A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to ...

  2. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

    ... antibody Patients in Expansion Phase, Cohorts 2 and 3; Previously ... Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline ...

  3. A Study to Evaluate the Safety and Effectiveness of JBH492 in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma - Mayo Clinic

    ... monoclonal antibody administration. Any prior history of treatment with maytansine (DM1 or DM4)-based ADC. Known intolerance to a maytansinoid. Patients ...

  4. Department of Immunology - Mayo Clinic Research

    Chronic inflammation; Infections; Tissue, organ and bone marrow transplantation. Departmental faculty also have oversight responsibilities for the Antibody ...

  5. Publications - Madiha Fida, M.B.B.S. - Mayo Clinic

    ... monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023; 9 (2):veac104 Epub 2022 Nov 05. View PubMed ...

  6. A Study to Evaluate the Safety and Effectiveness of MOR202 in Anti-PLA2R Antibody-positive Membranous Nephropathy - Mayo Clinic

    The purpose of this study is to assess the safety and tolerability of MOR202 treatment in subjects with Antibody Positive Membranous Nephropathy (aMN).

  7. ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer - Mayo Clinic

    Prior antibody treatment for cancer must have been ... Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal ...

  8. MEDI5395 Advanced Solid Tumors - Clinical Trials

    At least 28 days must have elapsed since non-immunotherapy monoclonal antibody treatment (for example trastuzumab, cetuximab, bevacizumab, or panitumumab); ...

  9. Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) - Mayo Clinic

    * previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) * active autoimmune disease requiring immunosuppressive ...

  10. Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis - Mayo Clinic

    Secondary or familial amyloidosis; · Life expectancy of < 3 months; · Symptomatic multiple myeloma; · Hypersensitivities to other monoclonal antibodies; · Known HIV ...